Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.47 |
| ▸ | CTSD | P07339 | 9/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | FSHR | P23945 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446897 | 0.88 | BACE1 (0.43) | BACE1CTSD | |
| SCHEMBL446250 | 0.86 | BACE1 (0.42) | BACE1CTSD | |
| SCHEMBL447030 | 0.78 | BACE1 (0.49) | BACE1CTSDCYP2C9 | |
| SCHEMBL446899 | 0.76 | BACE1 (0.46) | BACE1CTSD | |
| SCHEMBL2557900 | 0.76 | BACE1 (0.36) | BACE1CTSDCYP2C9 | |
| SCHEMBL447340 | 0.74 | BACE1 (0.45) | BACE1CTSDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL446464 | 0.72 | BACE1 (0.53) | BACE1CTSD | |
| SCHEMBL445389 | 0.70 | BACE1 (0.65) | BACE1CTSD | |
| SCHEMBL446300 | 0.70 | BACE1 (0.58) | BACE1CTSDMAPT | |
| SCHEMBL15817342 | 0.70 | BACE1 (0.52) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | BACE1 2/4885CTSD 427/4885CYP1A2 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.